• Users Online: 589
  • Print this page
  • Email this page


 
 
Table of Contents
LETTER TO EDITOR
Year : 2022  |  Volume : 5  |  Issue : 1  |  Page : 176-177

Authors' reply to Jaiswal and Chanana


1 Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India
2 Department of Pathology (Molecular Diagnostics), Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India

Date of Submission30-Jan-2022
Date of Decision18-Feb-2022
Date of Acceptance18-Feb-2022
Date of Web Publication31-Mar-2022

Correspondence Address:
Ullas Batra
Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Center, Sector 5, Rohini, Sir Chhotu Ram Marg, New Delhi - 110 085
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/crst.crst_62_22

Rights and Permissions

How to cite this article:
Batra U, Nathany S, Diwan H. Authors' reply to Jaiswal and Chanana. Cancer Res Stat Treat 2022;5:176-7

How to cite this URL:
Batra U, Nathany S, Diwan H. Authors' reply to Jaiswal and Chanana. Cancer Res Stat Treat [serial online] 2022 [cited 2022 May 28];5:176-7. Available from: https://www.crstonline.com/text.asp?2022/5/1/176/342410



We appreciate the expository comments of Jaiswal and Chanana[1] on our article, “RET in non-small cell lung carcinoma: A narrative review.”[2] Rearranged during transfection (RET) gene rearrangements are described in 1%–2% of all non-small-cell lung carcinomas (NSCLCs), with KIF5B being the most common fusion partner.[3],[4] These are more often encountered in young, never-smoker patients with solid variants of adenocarcinoma. Although there is paucity of data predicting the outcome of this rare entity, few studies have emphatically reported that patients with NSCLC harboring RET fusion have worse prognosis.[3] With the approval of selpercatinib and pralsetinib, RET rearrangements joined the ranks of targetable molecular alterations in NSCLC.

We are in consensus with Jaiswal and Chanana that the LIBRETTO-001 and ARROW trials predominantly included pretreated RET-rearranged NSCLCs, with few treatment-naïve patients. However, the ARROW trial reported an objective response rate (ORR) of 73% in the treatment-naïve group (n = 29) compared to 61% in the pretreated group (n = 91).[5] The ongoing trials will better elucidate the ORR and progression-free survival (PFS) of treatment-naïve patients with RET-rearranged NSCLC. Meanwhile, the National Comprehensive Cancer Network has recommended the use of selpercatinib and pralsetinib in the first or subsequent lines of treatment. The question of whether to use these selective RET inhibitors alone or with chemotherapy will be answered by the ongoing ARROW and LIBRETT0-431 trials.

We share Jaiswal and Chanana's concern about the development of resistance to these selective RET inhibitors. The G810R/S/C RET mutation has been described in two patients progressing on selpercatinib till date.[6] TPX-0046, a RET/ Sarcome (SRC) inhibitor, is currently being studied in a Phase I trial (NCT04161391) to assess its potential to overcome resistance to RET inhibitors caused by the G810 mutation.[2] However, more studies and trials are necessary to delve into the mechanism of resistance and explore therapies to overcome resistance.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Jaiswal A, Chanana R. Are we there RET? Cancer Res Stat Treat 2022;5:175-6.  Back to cited text no. 1
  [Full text]  
2.
Nathany S, Diwan H, Batra U. RET in non-small cell lung carcinoma: A narrative review. Cancer Res Stat Treat 2021;4:702-8.  Back to cited text no. 2
  [Full text]  
3.
Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, RET, by DNA rearrangement. Cell 1985;42:581-8.  Back to cited text no. 3
    
4.
Batra U, Sharma M, Nathany S, Soni S, Bansal A, Jain P, et al. Biomarker testing in non-small cell lung carcinoma – More is better: A case series. Cancer Res Stat Treat 2020;3:742-7.  Back to cited text no. 4
  [Full text]  
5.
Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): A multi-cohort, open-label, phase 1/2 study. Lancet Oncol 2021;22:959-69.  Back to cited text no. 5
    
6.
Drusbosky LM, Rodriguez E, Dawar R, Ikpeazu CV. Therapeutic strategies in RET gene rearranged non-small cell lung cancer. J Hematol Oncol 2021;14:50.  Back to cited text no. 6
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed114    
    Printed6    
    Emailed0    
    PDF Downloaded9    
    Comments [Add]    

Recommend this journal